Author
@Quantumup1 Quantumup1
grade Cx.com/Quantumup1 ↗
Real-time, attributive firehose of sell-side biotech analyst actions and catalysts
Quote-tweets and relays Wall Street analyst actions on biote
trader score
+0.10
hit rate
53%
mean α
+0.06%
signals 14d
82
Grade = how their written analysis reads (A best). Trader score = how their last-20 timestamped calls performed vs SPY.
Their picks, scored
Across their last 15 scored bets: 53% hit rate, +0.06% mean alpha, trader score +0.10. Their last-14d mentions, direction-adjusted, have moved -5.7% since posting (mean over 42 mentions with price data).
Recent signals15receipts included
| date (PT) | ticker | author | sent | what they said | since then | receipt |
|---|---|---|---|---|---|---|
| 2026-10-16 | KARD | @Quantumup1 | +0.40 | William Blair initiated Kardigan at Outperform with a $38 DCF valuation and cited 2027 catalysts. | · | tweet ↗ |
| 2026-10-16 | PVLA | @Quantumup1 | +0.40 | Raymond James reiterated Strong Buy on Palvella with a $226 target after supportive pediatric data. | · | tweet ↗ |
| 2026-10-16 | PVLA | @Quantumup1 | +0.40 | William Blair initiated Palvella at Outperform with a $266 DCF valuation and bullish launch assumptions. | · | tweet ↗ |
| 2026-10-16 | HALO | @Quantumup1 | +0.40 | H.C. Wainwright reiterated Buy on Halozyme with a $130 target and cited potential royalty expansion. | · | tweet ↗ |
| 2026-10-16 | SPCX | @Quantumup1 | +0.40 | Evercore raised its SPCX target to $275 from $230 and reiterated Outperform. | · | tweet ↗ |
| 2026-10-16 | EWTX | @Quantumup1 | +0.40 | William Blair initiated Edgewise at Outperform with a $53 valuation and identified multiple clinical catalysts. | · | tweet ↗ |
| 2026-10-16 | IDYA | @Quantumup1 | +0.40 | William Blair initiated IDEAYA at Outperform and expressed bullishness on darovasertib's launch prospects. | +5.7% | tweet ↗ |
| 2026-10-15 | PRAX | @Quantumup1 | +0.40 | JPMorgan rated Praxis Overweight with a $700 target and placed it on a positive catalyst watch list. | +1.9% | tweet ↗ |
| 2026-10-15 | CYTK | @Quantumup1 | +0.40 | William Blair initiated Cytokinetics at Outperform with a $101 DCF valuation and a bullish launch outlook. | -4.2% | tweet ↗ |
| 2026-10-15 | COAG | @Quantumup1 | +0.40 | Rodman & Renshaw initiated Hemab at Buy with a $56 price target. | · | tweet ↗ |
| 2026-10-15 | OBIO | @Quantumup1 | +0.40 | Piper Sandler reiterated Overweight on OBIO with a $12 target and urged investors to build positions. | · | tweet ↗ |
| 2026-10-15 | PRAX | @Quantumup1 | +0.40 | UBS initiated Praxis at Buy with a $706 target ahead of a January 2027 FDA decision. | +1.9% | tweet ↗ |
| 2026-10-15 | LQDA | @Quantumup1 | +0.40 | H.C. Wainwright raised Liquidia's target to $65 from $58 and reiterated Buy after a legal settlement. | +22.6% | tweet ↗ |
| 2026-10-14 | IDYA | @Quantumup1 | +0.40 | Stifel maintains Buy on IDEAYA with a $48 target and models $1.42 billion of 2035 product revenue. | +2.5% | tweet ↗ |
| 2026-10-14 | DOCN | @Quantumup1 | +0.40 | Oppenheimer raised DOCN's target to $220 from $190 while BofA maintained Buy with a $200 target. | -14.7% | tweet ↗ |
Grade is our human read-worthiness rating; trader score is a rolling 20-bet hit-rate/alpha composite — different things, often disagreeing. “Since then” is direction-unaware in the table; the summary line above adjusts for which way they leaned.